1887

Chapter 20 : Macrophage Proresolving Mediators—the When and Where

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Macrophage Proresolving Mediators—the When and Where, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap20-1.gif /docserver/preview/fulltext/10.1128/9781555819194/9781555819187_Chap20-2.gif

Abstract:

Inflammation is the organism’s response to local injury in vascularized tissues programmed to traffic leukocytes and plasma delivery to an injured site or point of bacterial invasion ( ); this protective response, when uncontrolled in humans, is associated with many widely occurring diseases. These include cardiovascular, metabolic, and the classic inflammatory diseases, e.g., arthritis and periodontal disease, along with cancers (reviewed in reference ). Nonresolving inflammation is now widely acknowledged as a major driver in most of these diseases (for a review, see reference ). The classical view of the resolution phase of the acute inflammatory response as understood and presented in pathology textbooks ( ) as well as in medical dictionaries ( ) was that local inflammatory chemical messengers and cells were diluted at the site (dilution of chemotactic gradient), hence halting further leukocyte recruitment and resolving the exudate or battlefield of inflammation ( ). The historical perspective on the origins and concepts in the medical community regarding the resolution of inflammation apparently trace back as early as 11th-century Europe, and interested readers can refer to a recent review ( ).

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

SPM identification in human macrophages: regulation during efferocytosis and by neutrophil microparticles. Macrophages were incubated with PMN microparticles before addition of apoptotic (Apo) PMNs. Representative MRM traces for identified LMs. Accompanying MS/MS spectra used for SPM identification. Specific bioactive LM and precursor/pathway markers where Q1, M-H (parent ion); and Q3, diagnostic ion in the MS/MS (daughter ion), along with mean ± standard error of the mean (SEM) values for each of the mediators are identified. Quantification and values obtained after PMN (3 × 10 PMNs) and microparticle (2 × 10 microparticles) incubations. The detection limit was ∼1 pg. *Below limits. = 4 distinct cell preparations. See reference and the text for further details.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Upregulation of SPMs in macrophages (Mɸ) by apoptotic PMNs and PMN microparticles (MPs). Incubations were conducted as in Fig. 1 ; LMs were identified and quantified by LC-MS/MS. D-series resolvins, protectins, and maresins. Lipoxins. Prostaglandins and thromboxanes. Results are expressed as mean ± SEM; = 4 distinct cell preparations. * < 0.05 versus macrophage group; ** < 0.01 versus macrophage group; < 0.05 versus macrophage plus Apo PMN group. Uptake of the carboxyfluorescein diacetate succinimidyl ester (CFDA)-labeled Apo PMNs was monitored after incubation with the indicated MP concentrations. Results are expressed as mean ± SEM ( = 4 distinct cell preparations). * < 0.05 versus macrophage plus PMN group; ** < 0.01 versus macrophage plus Apo PMN group. Schematic highlighting the contribution of apoptotic PMNs and MPs to SPM biosynthesis in macrophages. See reference and the text for further details.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Distinct macrophage subtypes display characteristic LM profiles. Human M1 and M2 macrophages were obtained by incubating peripheral blood monocytes with granulocyte-macrophage colony-stimulating factor, gamma interferon, and lipopolysaccharide or macrophage colony-stimulating factor and IL-4, respectively, and LM profiles assessed by LC-MS/MS. Results are representative on = 6 to 8 separate cell preparations. The original results were obtained in reference and are replotted here.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

The macrophage-derived proresolving mediator MaR1 stimulates tissue regeneration. Anterior portions of brown planaria were surgically removed, planaria were exposed to vehicle or MaR1, and regeneration was assessed 4 days after surgery using fluorescently conjugated lectin to visualize secretory cells. After surgery, planaria were kept in water-containing vehicle (Veh) or the indicated concentrations of MaR1. We direct interested readers to reference for detailed experimental conditions. Results are mean ± SEM ( = 5 planaria/group). * < 0.05; ** < 0.01; *** < 0.001 versus vehicle alone.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Maresins and RvD1 promote macrophage phenotype switch. M1 macrophages were incubated with vehicle, 13,14-epoxy-maresin, MaR1, or RvD1 for 6 h. Expression of M1 (CD54, CD80) and M2 (CD163, CD206) was assessed by flow cytometry using fluorescently conjugated antibodies. Results are representative of = 3 for each incubation condition. MFI, mean fluorescence intensity. See the text for additional details and reference for the original data set.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 6
Figure 6

Maresin biosynthesis and actions. DHA is converted by human 12-LOX through a lipoxygenase reaction involving the abstraction of hydrogen and the antarafacial addition of molecular oxygen at carbon 14 to produce 14-HpDHA, which is also converted to the 13,14-epoxide by the same enzyme ( ), denoted 13,14-epoxide-maresin, which is further converted to the bioactive MaR1, which promotes resolution, reduces pain signaling, and promotes tissue regeneration. See the text for further details, as well as references , and . The epoxide 13,14-epoxy-maresin is also bioactive and inhibits LTA hydrolase, limiting the production of LTB as well as the conversion of AA to 12-HpETE. These actions of the maresin epoxide indicate that activation of the pathway leads to downregulation of proinflammatory mediators during resolution.

Citation: Dalli J, Serhan C. 2017. Macrophage Proresolving Mediators—the When and Where, p 367-383. In Gordon S (ed), Myeloid Cells in Health and Disease. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.MCHD-0001-2014
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819194.chap20
1. Majno G,, Joris I . 2004. Cells, Tissues, and Disease: Principles of General Pathology, 2nd ed. Oxford University Press, New York, NY.
2. Serhan CN . 2010. Novel resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 177 : 15761591.[PubMed] [CrossRef]
3. Nathan C,, Ding A . 2010. Nonresolving inflammation. Cell 140 : 871882.[PubMed] [CrossRef]
4. Robbins SL,, Cotran R . 1979. Pathologic Basis of Disease, 2nd ed. W.B. Saunders Co, Philadelphia, PA.
5. Taber CW . 1970. Taber’s Cyclopedic Medical Dictionary, 11th ed. F. A. Davis Co, Philadelphia, PA.
6. Willoughby DA,, Moore AR,, Colville-Nash PR,, Gilroy D . 2000. Resolution of inflammation. Int J Immunopharmacol 22 : 11311135.[PubMed] [CrossRef]
7. Serhan CN,, Clish CB,, Brannon J,, Colgan SP,, Chiang N,, Gronert K . 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 : 11971204.[PubMed] [CrossRef]
8. Serhan CN . 2011. The resolution of inflammation: the devil in the flask and in the details. FASEB J 25 : 14411448.[PubMed] [CrossRef]
9. Cotran RS,, Kumar V,, Collins T . 1999. Robbins Pathologic Basis of Disease, 6th ed, p. 78, W.B. Saunders Co, Philadelphia, PA.
10. Lammermann T,, Afonso PV,, Angermann BR,, Wang JM,, Kastenmüller W,, Parent CA,, Germain RN . 2013. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo . Nature 498 : 371375.[PubMed] [CrossRef]
11. Malawista SE,, de Boisfleury Chevance A,, van Damme J,, Serhan CN . 2008. Tonic inhibition of chemotaxis in human plasma. Proc Natl Acad Sci U S A 105 : 1794917954.[PubMed] [CrossRef]
12. Samuelsson B,, Dahlén SE,, Lindgren ,, Rouzer CA,, Serhan CN . 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 : 11711176.[PubMed] [CrossRef]
13. Samuelsson B . 2012. Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 287 : 1007010080.[PubMed] [CrossRef]
14. Vane JR . 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin, p 181206. In Nobel Foundation (ed), Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Almqvist & Wiksell, Stockholm, Sweden.
15. Levy BD,, Clish CB,, Schmidt B,, Gronert K,, Serhan CN . 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2 : 612619.[PubMed] [CrossRef]
16. Serhan CN,, Brain SD,, Buckley CD,, Gilroy DW,, Haslett C,, O’Neill LA,, Perretti M,, Rossi AG,, Wallace JL . 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21 : 325332.[PubMed] [CrossRef]
17. Serhan CN,, Savill J . 2005. Resolution of inflammation: the beginning programs the end. Nat Immunol 6 : 11911197.[PubMed] [CrossRef]
18. Serhan CN,, Hong S,, Gronert K,, Colgan SP,, Devchand PR,, Mirick G,, Moussignac RL . 2002. Resolvins: a family of bioactive products of omega-fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196 : 10251037.[PubMed] [CrossRef]
19. Bannenberg GL,, Chiang N,, Ariel A,, Arita M,, Tjonahen E,, Gotlinger KH,, Hong S,, Serhan CN . 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174 : 43454355.[PubMed] [CrossRef]
20. Schwab JM,, Chiang N,, Arita M,, Serhan CN . 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 : 869874.[PubMed] [CrossRef]
21. Serhan CN . 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510 : 92101.[PubMed] [CrossRef]
22. Tauber AI,, Chernyak L . 1991. Metchnikoff and the Origins of Immunology: from Metaphor to Theory. Oxford University Press, New York, NY.
23. Gordon S . 2007. The macrophage: past, present and future. Eur J Immunol 37(Suppl 1): S9S17.[PubMed] [CrossRef]
24. Savill JS,, Wyllie AH,, Henson JE,, Walport MJ,, Henson PM,, Haslett C . 1989. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83 : 865875.[PubMed] [CrossRef]
25. Buckley CD,, Gilroy DW,, Serhan CN . 2014. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40 : 315327.[PubMed] [CrossRef]
26. Devchand PR,, Arita M,, Hong S,, Bannenberg G,, Moussignac RL,, Gronert K,, Serhan CN . 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host-defense. FASEB J 17 : 652659.[PubMed] [CrossRef]
27. Krishnamoorthy S,, Recchiuti A,, Chiang N,, Fredman G,, Serhan CN . 2012. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180 : 20182027.[PubMed] [CrossRef]
28. Gao L,, Faibish D,, Fredman G,, Herrera BS,, Chiang N,, Serhan CN,, Van Dyke TE,, Gyurko R . 2013. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 190 : 689694.[PubMed] [CrossRef]
29. Norling LV,, Dalli J,, Flower RJ,, Serhan CN,, Perretti M . 2012. Resolvin D1 limits polymorphonuclear leukocytes recruitment to inflammatory loci: receptor dependent actions. Arterioscler Thromb Vasc Biol 32 : 19701978.[PubMed] [CrossRef]
30. Brancaleone V,, Gobbetti T,, Cenac N,, le Faouder P,, Colom B,, Flower RJ,, Vergnolle N,, Nourshargh S,, Perretti M . 2013. A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122 : 608617.[PubMed] [CrossRef]
31. Serhan CN,, Chiang N . 2013. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13 : 632640.[PubMed] [CrossRef]
32. Chiang N,, Dalli J,, Colas RA,, Serhan CN . 2015. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med 212 : 12031217.[PubMed] [CrossRef]
33. Li D,, Hodges RR,, Jiao J,, Carozza RB,, Shatos MA,, Chiang N,, Serhan CN,, Dartt DA . 2013. Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol 6 : 11191130.[PubMed] [CrossRef]
34. Cooray SN,, Gobbetti T,, Montero-Melendez T,, McArthur S,, Thompson D,, Clark AJ,, Flower RJ,, Perretti M . 2013. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A 110 : 1823218237.[PubMed] [CrossRef]
35. Lu Y,, Hong S,, Tjonahen E,, Serhan CN . 2005. Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. J Lipid Res 46 : 790802.[PubMed] [CrossRef]
36. Serhan CN,, Petasis NA . 2011. Resolvins and protectins in inflammation-resolution. Chem Rev 111 : 59225943.[PubMed] [CrossRef]
37. Serhan CN,, Dalli J,, Karamnov S,, Choi A,, Park CK,, Xu ZZ,, Ji RR,, Zhu M,, Petasis NA . 2012. Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26 : 17551765.[PubMed] [CrossRef]
38. Bento AF,, Claudino RF,, Dutra RC,, Marcon R,, Calixto JB . 2011. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 187 : 19571969.[PubMed] [CrossRef]
39. Chan MM,, Moore AR . 2010. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol 184 : 64186426.[PubMed] [CrossRef]
40. Bang S,, Yoo S,, Yang TJ,, Cho H,, Hwang SW . 2012. 17(R)-Resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol 165 : 683692.[PubMed] [CrossRef]
41. Rajasagi NK,, Reddy PB,, Suryawanshi A,, Mulik S,, Gjorstrup P,, Rouse BT . 2011. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol 186 : 17351746.[PubMed] [CrossRef]
42. Titos E,, Rius B,, González-Périz A,, López-Vicario C,, Morán-Salvador E,, Martínez-Clemente M,, Arroyo V,, Clària J . 2011. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 187 : 54085418.[PubMed] [CrossRef]
43. White PJ,, Arita M,, Taguchi R,, Kang JX,, Marette A . 2010. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 59 : 30663073.[PubMed] [CrossRef]
44. Morris T,, Stables M,, Colville-Nash P,, Newson J,, Bellingan G,, de Souza PM,, Gilroy DW . 2010. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc Natl Acad Sci U S A 107 : 88428847.[PubMed] [CrossRef]
45. Morris T,, Stables M,, Hobbs A,, de Souza P,, Colville-Nash P,, Warner T,, Newson J,, Bellingan G,, Gilroy DW . 2009. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183 : 20892096.[PubMed] [CrossRef]
46. Psychogios N,, Hau DD,, Peng J,, Guo AC,, Mandal R,, Bouatra S,, Sinelnikov I,, Krishnamurthy R,, Eisner R,, Gautam B,, Young N,, Xia J,, Knox C,, Dong E,, Huang P,, Hollander Z,, Pedersen TL,, Smith SR,, Bamforth F,, Greiner R,, McManus B,, Newman JW,, Goodfriend T,, Wishart DS . 2011. The human serum metabolome. PLoS One 6 : e16957. doi:10.1371/journal.pone.0016957. [PubMed] [CrossRef]
47. Raatz SK,, Golovko MY,, Brose SA,, Rosenberger TA,, Burr GS,, Wolters WR,, Picklo MJ Sr . 2011. Baking reduces prostaglandin, resolvin, and hydroxy-fatty acid content of farm-raised Atlantic salmon (Salmo salar). J Agric Food Chem 59 : 1127811286.[PubMed] [CrossRef]
48. Tobin DM,, Roca FJ,, Oh SF,, McFarland R,, Vickery TW,, Ray JP,, Ko DC,, Zou Y,, Bang ND,, Chau TT,, Vary JC,, Hawn TR,, Dunstan SJ,, Farrar JJ,, Thwaites GE,, King MC,, Serhan CN,, Ramakrishnan L . 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148 : 434446.[PubMed] [CrossRef]
49. Perretti M,, Dalli J . 2009. Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol 158 : 936946.[PubMed] [CrossRef]
50. Chiang N,, Shinohara M,, Dalli J,, Mirakaj V,, Kibi M,, Choi AMK,, Serhan CN . 2013. Inhaled carbon monoxide accelerates resolution of inflammation via unique pro-resolving mediator–heme oxygenase-1 circuits. J Immunol 190 : 63786388.[PubMed] [CrossRef]
51. Flannigan KL,, Agbor TA,, Blackler RW,, Kim JJ,, Khan WI,, Verdu EF,, Ferraz JG,, Wallace JL . 2014. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proc Natl Acad Sci U S A 111 : 1355913564.[PubMed] [CrossRef]
52. Dinarello CA . 2010. Anti-inflammatory agents: present and future. Cell 140 : 935950.[PubMed] [CrossRef]
53. Yang R,, Chiang N,, Oh SF,, Serhan CN . 2011. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol Chapter 14 : Unit 14.26. doi:10.1002/0471142735.im1426s95. [CrossRef]
54. Boilard E,, Nigrovic PA,, Larabee K,, Watts GF,, Coblyn JS,, Weinblatt ME,, Massarotti EM,, Remold-O’Donnell E,, Farndale RW,, Ware J,, Lee DM . 2010. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327 : 580583.[PubMed] [CrossRef]
55. Wolf P . 1967. The nature and significance of platelet products in human plasma. Br J Haematol 13 : 269288.[PubMed] [CrossRef]
56. Norling LV,, Dalli J . 2013. Microparticles are novel effectors of immunity. Curr Opin Pharmacol 13 : 570575.[PubMed] [CrossRef]
57. Hunter MP,, Ismail N,, Zhang X,, Aguda BD,, Lee EJ,, Yu L,, Xiao T,, Schafer J,, Lee ML,, Schmittgen TD,, Nana-Sinkam SP,, Jarjoura D,, Marsh CB . 2008. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3 : e3694. doi:10.1371/journal.pone.0003694. [PubMed] [CrossRef]
58. Cantaluppi V,, Gatti S,, Medica D,, Figliolini F,, Bruno S,, Deregibus MC,, Sordi A,, Biancone L,, Tetta C,, Camussi G . 2012. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82 : 412427.[PubMed] [CrossRef]
59. Brown GT,, McIntyre TM . 2011. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles. J Immunol 186 : 54895496.[PubMed] [CrossRef]
60. Agouni A,, Mostefai HA,, Porro C,, Carusio N,, Favre J,, Richard V,, Henrion D,, Martínez MC,, Andriantsitohaina R . 2007. Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. FASEB J 21 : 27352741.[PubMed] [CrossRef]
61. Mack M,, Kleinschmidt A,, Bruhl H,, Klier C,, Nelson PJ,, Cihak J,, Plachy J,, Stangassinger M,, Erfle V,, Schlondorff D . 2000. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 6 : 769775.[PubMed] [CrossRef]
62. Dalli J,, Norling LV,, Renshaw D,, Cooper D,, Leung KY,, Perretti M . 2008. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 112 : 25122519.[PubMed] [CrossRef]
63. Norling LV,, Spite M,, Yang R,, Flower RJ,, Perretti M,, Serhan CN . 2011. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 186 : 55435547.[PubMed] [CrossRef]
64. Dalli J,, Serhan CN . 2012. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120 : e60e72. doi:10.1182/blood-2012-04-423525. [CrossRef]
65. Dalli J,, Norling LV,, Montero-Melendez T,, Federici Canova D,, Lashin H,, Pavlov AM,, Sukhorukov GB,, Hinds CJ,, Perretti M . 2014. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med 6 : 2742.[PubMed] [CrossRef]
66. Arnardottir HH,, Dalli J,, Colas RA,, Shinohara M,, Serhan CN . 2014. Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol 193 : 42354244.[PubMed] [CrossRef]
67. Ji RR,, Xu ZZ,, Gao YJ . 2014. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13 : 533548.[PubMed] [CrossRef]
68. Mirakaj V,, Dalli J,, Granja T,, Rosenberger P,, Serhan CN . 2014. Vagus nerve controls resolution and pro-resolving mediators of inflammation. J Exp Med 211 : 10371048.[PubMed] [CrossRef]
69. Kasuga K,, Yang R,, Porter TF,, Agrawal N,, Petasis NA,, Irimia D,, Toner M,, Serhan CN . 2008. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol 181 : 86778687.[PubMed] [CrossRef]
70. Bellora F,, Castriconi R,, Dondero A,, Reggiardo G,, Moretta L,, Mantovani A,, Moretta A,, Bottino C . 2010. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A 107 : 2165921664.[PubMed] [CrossRef]
71. Serhan CN,, Yang R,, Martinod K,, Kasuga K,, Pillai PS,, Porter TF,, Oh SF,, Spite M . 2009. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J Exp Med 206 : 1523.[PubMed] [CrossRef]
72. Pellettieri J,, Fitzgerald P,, Watanabe S,, Mancuso J,, Green DR,, Alvarado AS . 2010. Cell death and tissue remodeling in planarian regeneration. Dev Biol 338 : 7685.[PubMed] [CrossRef]
73. Dalli J,, Zhu M,, Vlasenko NA,, Deng B,, Haeggström JZ,, Petasis NA,, Serhan CN . 2013. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 27 : 25732583.[PubMed] [CrossRef]
74. Libby P,, Tabas I,, Fredman G,, Fisher EA . 2014. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114 : 18671879.[PubMed] [CrossRef]
75. Legg K . 2012. Infectious disease: pro-resolving lipids offer a helping hand to antibiotics. Nat Rev Drug Discov 11 : 441. [PubMed] [CrossRef]
76. Markworth JF,, Vella LD,, Lingard BS,, Tull DL,, Rupasinghe TW,, Sinclair AJ,, Maddipati KR,, Cameron-Smith D . 2013. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am J Physiol Regul Integr Comp Physiol 305 : R1281R1296.[PubMed] [CrossRef]
77. Sasaki A,, Fukuda H,, Shiida N,, Tanaka N,, Furugen A,, Ogura J,, Shuto S,, Mano N,, Yamaguchi H . 2015. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS. Anal Bioanal Chem 407 : 16251639.[PubMed] [CrossRef]
78. Colas RA,, Shinohara M,, Dalli J,, Chiang N,, Serhan CN . 2014. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307 : C39C54.[PubMed] [CrossRef]
79. Barden A,, Mas E,, Croft KD,, Phillips M,, Mori TA . 2014. Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res 55 : 24012407.[PubMed] [CrossRef]
80. Jones ML,, Mark PJ,, Keelan JA,, Barden A,, Mas E,, Mori TA,, Waddell BJ . 2013. Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J Lipid Res 54 : 22472254.[PubMed] [CrossRef]
81. Mas E,, Croft KD,, Zahra P,, Barden A,, Mori TA . 2012. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58 : 14761484.[PubMed] [CrossRef]
82. Keelan JA,, Mas E,, D’Vaz N,, Dunstan JA,, Li S,, Barden AE,, Mark PJ,, Waddell BJ,, Prescott SL,, Mori TA . 2015. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. Reproduction 149 : 171178.[PubMed] [CrossRef]
83. Weiss GA,, Troxler H,, Klinke G,, Rogler D,, Braegger C,, Hersberger M . 2013. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis 12 : 89. doi:10.1186/1476-511X-12-89. [PubMed] [CrossRef]
84. Mas E,, Barden A,, Burke V,, Beilin LJ,, Watts GF,, Huang RC,, Puddey IB,, Irish AB,, Mori TA . 2015. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr 35 : 331336.[PubMed] [CrossRef]
85. Arnardottir H,, Orr SK,, Dalli J,, Serhan CN . 2015. Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol doi:10.1038/mi.2015.99. [CrossRef]
86. Arita M,, Oh S,, Chonan T,, Hong S,, Elangovan S,, Sun YP,, Uddin J,, Petasis NA,, Serhan CN . 2006. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem 281 : 2284722854.[PubMed] [CrossRef]
87. Hasturk H,, Kantarci A,, Ohira T,, Arita M,, Ebrahimi N,, Chiang N,, Petasis NA,, Levy BD,, Serhan CN,, Van Dyke TE . 2006. RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J 20 : 401403.[PubMed]
88. Deng B,, Wang CW,, Arnardottir HH,, Li Y,, Cheng CY,, Dalli J,, Serhan CN . 2014. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLoS One 9 : e102362. doi:10.1371/journal.pone.0102362. [PubMed] [CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error